Immature Teratoma of the Ovary: Understanding Your Pathology Report

by Emily Goebel, MD FRCPC
April 19, 2026

Immature teratoma of the ovary is a rare type of malignant (cancerous) ovarian tumor. Despite sharing the word “teratoma” with the common, noncancerous mature teratoma (also called a dermoid cyst), an immature teratoma is a fundamentally different diagnosis — one that requires careful staging and, in many cases, treatment beyond surgery. The word “immature” refers to the fact that the tumor contains incompletely developed tissue that resembles tissue found in a developing embryo or fetus, particularly immature nerve tissue. This immature tissue is what makes the tumor malignant and gives it the potential to spread to other parts of the body. Immature teratoma is most often diagnosed in children, teenagers, and young women — typically before the age of 30 — making it one of the more common ovarian cancers in young patients. The good news is that even when it has spread, the prognosis is generally much better than for most other ovarian cancers, and a cure is achievable in the majority of cases. This article will help you understand the findings in your pathology report — what each term means and why it matters for your care.

What are the symptoms?

Most patients develop symptoms related to a pelvic or abdominal mass. Common symptoms include abdominal or pelvic pain, a feeling of fullness or swelling in the abdomen, a noticeable lump in the pelvic area, or irregular menstrual cycles. Because immature teratomas can grow relatively quickly, symptoms may develop over weeks to months.

Blood tests may occasionally show elevated levels of a protein called alpha-fetoprotein (AFP) — a protein produced in large amounts by the developing fetus but normally present only in very small amounts in adults. When AFP is elevated in a patient with a teratoma, it usually indicates that another type of germ cell tumor, a yolk sac tumor, is also present within the mass, either as a separate component or mixed with the teratoma. This is an important distinction because the presence of a yolk sac tumor affects staging and treatment.

What causes immature teratoma of the ovary?

The exact cause is not fully known. Like mature teratomas, immature teratomas develop from germ cells — specialized cells in the ovary that normally develop into eggs. These germ cells have the unusual ability to give rise to many different tissue types. In an immature teratoma, something goes wrong during this process, and the germ cell produces not only fully developed (mature) tissues such as skin and fat but also incompletely developed (immature) tissues — most characteristically, tissue resembling the developing nervous system. No inherited gene mutations are known to cause immature teratomas, and they are not associated with BRCA mutations or Lynch syndrome.

How is the diagnosis made?

The diagnosis is made after the tumor is removed at surgery and examined under the microscope by a pathologist. Imaging studies such as ultrasound, CT, or MRI can detect the mass, but cannot reliably distinguish an immature from a mature teratoma — that distinction can only be made by microscopic examination. If AFP is elevated on a blood test, this is an important finding that the pathologist takes into account when examining the tumor.

Under the microscope, an immature teratoma contains a mixture of mature tissues — the same kinds of fully developed skin, fat, cartilage, bone, or intestinal lining found in a benign mature teratoma — alongside areas of immature tissue. The defining and diagnostically critical feature is the presence of immature neuroectodermal tissue: clusters of small, dark, primitive-looking cells that resemble the nervous system in early fetal development. These clusters, sometimes called neuroepithelial rosettes or tubules, are what distinguish an immature teratoma from its benign counterpart. The more immature neural tissue is present, the higher the tumor grade.

Because other types of ovarian germ cell tumors — including yolk sac tumor, dysgerminoma, and embryonal carcinoma — can look similar in places or may be present alongside the immature teratoma, the pathologist carefully examines the entire specimen for any additional tumor components. Immunohistochemistry (IHC) — a technique that uses antibodies to detect specific proteins in the cells — may be used in difficult cases to confirm the diagnosis or identify mixed components.

Because the grade of an immature teratoma depends on the most immature area within the tumor, thorough sampling is essential. Pathology reports for immature teratomas often describe multiple tissue blocks submitted from different areas of the specimen — this is not unusual and reflects the care required to make an accurate diagnosis.

Once the diagnosis is confirmed, imaging — typically CT of the abdomen, pelvis, and chest — is performed to determine whether the tumor has spread beyond the ovary. This information, combined with findings at surgery and in the pathology report, determines the stage.

Histologic grade

Grading is one of the most important pieces of information in the pathology report for an immature teratoma. Unlike the grading systems used for epithelial ovarian cancers — which assess how abnormal the cells look overall — immature teratoma is graded specifically by how much immature neural tissue (tissue resembling the developing nervous system) is present. The reason neural tissue is the focus is that it is both the most common type of immature tissue in these tumors and the component most closely linked to aggressive behavior and risk of spread.

The grading system divides immature teratomas into three grades:

• Grade 1 — Only a very small amount of immature neural tissue is present. When the pathologist examines the tumor under the microscope, the total area of immature tissue is less than one low-power microscopic field — meaning it occupies a very small and limited region of the tumor. Grade 1 immature teratomas are considered low grade. They have an excellent prognosis, particularly when confined to the ovary, and many patients with grade 1 stage I tumors are cured with surgery alone.
• Grade 2 — A moderate amount of immature neural tissue is present, occupying between one and three low-power microscopic fields across the examined sections. Grade 2 tumors are considered high grade. They carry a greater risk of spread and recurrence than grade 1 tumors, and chemotherapy is typically recommended in addition to surgery for most patients.
• Grade 3 — Large amounts of immature neural tissue are present, occupying more than three low-power microscopic fields. Grade 3 tumors are also high grade and represent the most aggressive form of immature teratoma. Chemotherapy is standard treatment alongside surgery.

A practical point worth understanding: because grade is determined by the most immature area found anywhere in the tumor, a single small focus of high-grade tissue can upgrade an otherwise low-appearing tumor. This is why the pathologist examines multiple sections from different areas, and why the report may describe extensive sampling. It also means that a grade assigned on a small biopsy before surgery might change after the entire tumor is examined — the final grade in the surgical specimen is the one that guides treatment.

Gliomatosis peritonei

Gliomatosis peritonei is a finding in which deposits of mature glial tissue — a type of supporting nerve tissue — are found on the peritoneum, the thin membrane lining the inside of the abdominal cavity. It occurs in a subset of patients with immature teratoma and can look alarming on imaging or during surgery because deposits on the peritoneum are a feature of many advanced cancers.

However, gliomatosis peritonei is an important exception to the usual rule: although it is classified as stage III disease under the FIGO staging system — because tumor deposits are found outside the ovary on the peritoneum — it behaves in a fundamentally different way from stage III spread of most cancers. The deposits are composed of mature, fully developed tissue, not actively invasive cancer cells, and typically do not grow aggressively or cause harm. Most patients with gliomatosis peritonei have an excellent outcome, and the deposits often do not require treatment beyond removal of the primary tumor. Your oncologist will take this distinction into account when discussing your treatment plan.

Tumor spread

The pathologist examines all submitted tissue to determine whether the immature teratoma has spread beyond the ovary. Spread may involve the surface of the fallopian tube or uterus, the peritoneum, the omentum (the fatty tissue hanging from the stomach and intestines), lymph nodes, or distant organs. The presence and extent of spread — along with what was observed at surgery — determines the stage.

Unlike most ovarian carcinomas, which frequently present at advanced stages, most immature teratomas are confined to the ovary at diagnosis. However, higher-grade tumors are more likely to spread.

Ovarian capsule status

The outer covering of the ovary is called the capsule. Whether the capsule is intact or ruptured, and whether tumor is present on the outer surface, affects the stage:

• Intact capsule, no surface tumor — Suggests the tumor is still contained within the ovary, associated with an earlier stage.
• Ruptured capsule or tumor on the surface — Increases the stage, even when no spread to other organs is identified.
• Intraoperative rupture — Noted separately if the capsule ruptured during surgery, and also affects staging.

Lymphovascular invasion

Lymphovascular invasion means tumor cells have been found inside small blood vessels or lymphatic channels within the tissue. This finding suggests tumor cells may have had an opportunity to travel to lymph nodes or distant sites.

Lymph nodes

Lymph nodes are small, bean-shaped structures that help filter the body’s lymphatic fluid and support the immune system. Lymph nodes from the pelvis and along the major abdominal blood vessels (para-aortic nodes) may be removed and examined. If tumor cells are found in the lymph nodes, the stage increases.

The pathology report will describe:

• The total number of lymph nodes examined
• The number of lymph nodes containing tumor cells
• The size of the largest tumor deposit
• The location of any involved nodes (pelvic vs. para-aortic)

Lymph node deposits are classified by size. Isolated tumor cells (measuring 0.2 mm or less) are recorded as pN0(i+). Deposits between 0.2 mm and 10 mm are classified as pN1a (small metastases), and deposits larger than 10 mm are classified as pN1b (large metastases).

Pathologic stage (pTNM)

Staging describes how far the tumor has spread. Immature teratoma uses the same AJCC TNM / FIGO staging system applied to other ovarian tumors. The stage is determined by T (local tumor extent), N (lymph node involvement), and M (distant spread). M stage is determined by imaging and is not typically assigned in the pathology report unless distant spread was sampled at surgery.

Tumor stage (pT)

• pT1 (FIGO Stage I) — Tumor is limited to one or both ovaries.
  • pT1a — Tumor in one ovary; capsule intact; no tumor on the outer surface; no tumor cells in abdominal fluid.
  • pT1b — Tumor involves both ovaries; capsules intact; no tumor on the outer surface; no tumor cells in abdominal fluid.
  • pT1c — Tumor limited to one or both ovaries but with capsule rupture, tumor on the outer surface, or cancer cells in abdominal fluid or washings.
• pT2 (FIGO Stage II) — Tumor has spread beyond the ovaries into the pelvis.
  • pT2a — Spread to the uterus or fallopian tubes.
  • pT2b — Spread to other pelvic tissues.
• pT3 (FIGO Stage III) — Tumor has spread beyond the pelvis to the peritoneum or regional lymph nodes. Note: gliomatosis peritonei is classified as pT3 but has a much better prognosis than other forms of stage III disease — see the gliomatosis peritonei section above.
  • pT3a — Microscopic spread to the peritoneum outside the pelvis.
  • pT3b — Visible tumor deposits up to 2 cm on the peritoneum outside the pelvis.
  • pT3c — Visible tumor deposits larger than 2 cm, or spread to the outer surface of the liver or spleen.

Nodal stage (pN)

• pN0 — No cancer cells found in regional lymph nodes.
• pN0(i+) — Only isolated tumor cells (0.2 mm or less) found in lymph nodes.
• pN1 — Cancer cells present in regional lymph nodes.
  • pN1a — Tumor deposits up to 10 mm.
  • pN1b — Tumor deposits larger than 10 mm.

What is the prognosis?

The prognosis for immature teratoma is generally very good — significantly better than for the most common types of ovarian cancer. Even in advanced cases, cure is achievable with surgery and chemotherapy, and overall survival rates across all stages exceed 90% in most published series. This favorable outcome reflects both the chemotherapy sensitivity of germ cell tumors and the typically young age and good overall health of affected patients.

Prognosis is influenced primarily by stage and grade:

• Stage I, grade 1 — Survival approaches 100% with surgery alone. This is the most favorable group, and chemotherapy is generally not required.
• Stage I, grade 2 or 3 — Excellent prognosis with surgery plus chemotherapy. Most patients are cured.
• Stage II–III (excluding gliomatosis peritonei) — Very good prognosis with surgery plus chemotherapy. Long-term survival rates exceed 85–90% in most studies.
• Stage III with gliomatosis peritonei only — Excellent prognosis despite the stage III classification. Gliomatosis peritonei is a special case — see that section for details.
• Stage IV — Prognosis is less favorable but curative treatment remains possible in many patients. Response to platinum-based chemotherapy is typically good.

The presence of other germ cell tumor components (such as yolk sac tumor) alongside the immature teratoma may affect treatment planning and prognosis, and your oncologist will discuss this.

What happens after the diagnosis?

Treatment is planned by a multidisciplinary team. Because immature teratoma typically affects young patients — including children and teenagers — the team often includes a gynecologic oncologist and a pediatric oncologist working together.

Surgery is the first step. Because this tumor almost always affects only one ovary and occurs in young patients, fertility-sparing surgery — removing only the affected ovary and fallopian tube while leaving the uterus and other ovary intact — is the standard approach for most patients. This preserves the possibility of future pregnancy. Complete removal of the tumor (no residual disease) is the goal, and the surgeon will also inspect the peritoneum, omentum, and lymph nodes to assess for spread. A peritoneal wash — fluid collected from the abdominal cavity and examined for tumor cells — is typically performed as well.

After surgery, chemotherapy is recommended for most patients with grade 2 or grade 3 tumors, and for any patient with disease that has spread beyond the ovary (stage II or higher), regardless of grade. The standard chemotherapy regimen is BEP — bleomycin, etoposide, and cisplatin, which is highly effective against germ cell tumors. For patients with grade 1, stage I disease and an intact capsule, surgery alone may be sufficient, and a watch-and-wait approach with close surveillance is often appropriate.

Surveillance after treatment includes regular clinical assessments, serum AFP and other tumor marker monitoring, and imaging. Because recurrences, when they occur, are usually detectable early and remain chemotherapy-sensitive, outcomes after recurrence are also generally good.

Fertility is an important consideration for young patients. Because fertility-sparing surgery is standard, most patients retain the ability to become pregnant after treatment. The effects of BEP chemotherapy on long-term fertility should be discussed with your oncologist before treatment begins.

Questions to ask your doctor

• What grade is my immature teratoma — grade 1, 2, or 3 — and does that mean it is low grade or high grade?
• What stage is my tumor, and has it spread beyond the ovary?
• Was the tumor completely removed at surgery, and was capsule rupture noted?
• Was gliomatosis peritonei found, and how does that affect my stage and treatment plan?
• Were any other germ cell tumor components — such as yolk sac tumor — found alongside the immature teratoma?
• Was my AFP blood test elevated, and what does the result mean?
• Is chemotherapy recommended for my situation, and if so, which regimen?
• Was fertility-sparing surgery performed, and can I still become pregnant after treatment?
• What tumor markers should be monitored during follow-up, and how often?
• What signs or symptoms of recurrence should I watch for, and how quickly should I contact the team?
• What is my overall prognosis, and what does long-term follow-up look like?

Related articles

• Mature Teratoma of the Ovary
• Struma Ovarii
• Biomarkers and Molecular Testing